Bayer AG
Analysis Result: 4 out of 5 MUMAKS
Rating
This analysis assesses Bayer AG under the UMBRELLA strategy using the MUMAK method.
The valuation is conducted across five decision-making phases: Geopolitics, Industry, Fundamentals, Market Sentiment, and Technical Analysis.
The goal is not to predict the future precisely. The goal is orientation. We contextualize facts, demonstrate causal relationships, and structure a comprehensible decision logic.
We explain – you decide.
Geopolitics
Classification
The current geopolitical environment remains broadly supportive for global pharmaceutical and agricultural companies.
Key Takeaway
- The growing importance of food security, healthcare, and resilient supply chains supports long-term demand for Bayer AG’s products.
- The war in Ukraine, geopolitical tensions between the US and China, and the rising need for productive and sustainable agriculture are increasing the strategic importance of modern seed and crop protection technologies.
- The US remains Bayer’s most important single market, in both the pharma and agriculture segments. This gives the company exposure to an attractive market environment, but also makes it more vulnerable to political and regulatory changes and litigation.
- At the same time, regulatory and political risks are increasing. In particular, crop protection products, genetic technologies, and sustainability requirements are increasingly in the spotlight of governments and authorities in Europe, North America, and other key markets.
- Bayer is strategically positioned as one of the world’s leading life-science groups, with a strong presence in the US, Europe, and key international agricultural and pharmaceutical markets. This leaves the company well placed to benefit from long-term trends in health and nutrition.
MUMAK.me Assessment Phase 1: Positive = 1 MUMAK
Bayer AG
Geopolitics Rating: positive
Industry
Assessment
The pharmaceutical and agricultural industries continue to benefit from structural demand growth, high barriers to entry, and long-term global megatrends such as population growth, ageing societies, and food security.
Valuation comparison: Bayer vs. sector peers
| Metric | Bayer | Industry Average* | Rating |
|---|---|---|---|
| P/E Ratio | N/M (negative earnings) | approx. 16–22x | Discount |
| EV/EBITDA | approx. 5–6x | approx. 10–14x | Significant discount |
| Gross margin | approx. 57% | approx. 65–75% | Discount |
| Revenue Growth | approx. -2% to +1% | approx. 4–8% | Discount |
*Based on Novartis, Roche, Sanofi, Merck KGaA, Corteva, and other major pharmaceutical and agricultural companies.
Key Takeaway
- Rising demand for pharmaceuticals, advanced seed solutions, and efficient agriculture supports the sector’s long-term development.
- Trends such as precision agriculture, sustainable yield improvements, and innovation in pharmaceutical research provide planning certainty over multiple years.
- In particular, the agriculture business is among the world’s leading providers of seeds and crop protection products, while the pharma business benefits from a strong position in selected therapeutic areas.
- At the same time, the sector remains heavily regulated; pricing pressure in healthcare, stricter environmental requirements, and patent cycles remain key drivers of long-term profitability.
MUMAK.me Phase 2 Rating: Neutral = 0 MUMAK
Bayer AG
Industry Rating: neutral
Fundamentals
Assessment
Bayer AG’s fundamentals present a mixed picture. While profitability is improving significantly and operational progress is becoming visible, high leverage, legal risks, and weak cash flow development continue to weigh on the company.
Outlook 2026
| Key Figure | FY 2026e |
|---|---|
| Revenue | ~ EUR 45.5 billion |
| EBITDA | ~ EUR 9.65 billion |
| Free Operating Cash Flow | ~ EUR -1.5/-2.5 billion (including ~ EUR 5 billion for litigation payouts) |
| Group net debt | ~ EUR 32–33 billion (incl. litigation payouts) |
| Forward P/E (2026e) | ~ 15x |
Financial Metrics
| Key Figure | FY 2025 |
|---|---|
| Revenue FY2025 | EUR 45.8 billion (-2% vs. 2024) |
| EBITDA FY2025 | EUR 8.87 billion (+33.9% vs. 2024) |
| FOCF FY2025 | EUR 2.1 billion (-32.9% vs. 2024) |
| Revenue 2026e | ~ EUR 45.5 billion |
| EBITDA 2026e | ~ EUR 9.65 billion |
| FOCF 2026e | ~ EUR -1.5/-2.5 billion |
Bayer AG – Financial overview. Source: Bayer AG annual financial statements 2025, Bayer makes a solid start to the year and confirms currency-adjusted group guidance for 2026, MarketScreener valuation data, accessed in July 2026.
Key Takeaway
- Operational development remains stable despite a challenging market environment. Bayer achieved revenue of €45.8 billion in 2025, which corresponds to a slight decrease of 2% compared to the previous year.
- The Profitability improved significantly more than revenue development. EBITDA rose by 33.9% to €8.87 billion in 2025, benefiting from efficiency measures and operational improvements in the business segments.
- The Free Cash Flow remains a burden in the short term. After a decline of 32.9% to €2.1 billion in 2025, Bayer expects a negative Free Cash Flow of approximately -€1.5 to -€2.5 billion for 2026, mainly due to payments related to legal disputes and restructuring measures.
- Currently, the clarification of the situation regarding legal disputes, in particular, could support a re-evaluation of the stock.
- The strategic separation of the US glyphosate business into the new subsidiary “Ruveon” represents another important step toward reducing legal and business risks. This will create a clearer organizational separation between the operational Crop Science business and the legal disputes. In the long term, this could increase transparency, improve the risk profile, and support a re-rating of the Bayer share.
MUMAK.me Assessment Phase 3: Positive = 1 MUMAK
Bayer AG
Fundamentals Rating: positive
News, Analysts, and Market Sentiment
Assessment
Market sentiment toward Bayer AG has improved recently, but remains cautious due to glyphosate litigation, high leverage, and the expected negative free cash flow for 2026. Sentiment is supported by operational improvements, progress in restructuring, and positive analyst assessments.
Key Takeaway
- After the first quarter, Bayer confirmed its full-year outlook. Revenue came in at €13.4 billion, while EBITDA before special items rose by 9% to €4.45 billion. Group net income improved to €2.76 billion.
- At the end of June, Bayer achieved a major legal success before the US Supreme Court. The Court ruled 7-2 in Bayer’s favor, significantly strengthening the company’s position in the glyphosate proceedings. The decision is likely to rule out a large share of future “failure-to-warn” lawsuits and materially improves the chances of a final settlement of the remaining legal disputes.
- In early July, Bayer also announced that it will carve out the US glyphosate business into the new subsidiary “Ruveon”. Going forward, the company will take over production, pricing, and logistics for Roundup in the US. This organizational separation could improve the risk profile and, in the long term, opens up additional strategic options for the Group.
- Analysts remain largely positive and see further upside potential following the latest developments.
Analyst Consensus
| Average Recommendation | OUTPERFORM |
| Number of Analysts | 18 |
| Average Price Target | ~52 EUR |
| Upside to Average Target | approx. +6% |
| Upper Target | EUR 65.00 |
| Lower Target | EUR 40.00 |
Source: MarketScreener, retrieved in July 2026.
Interesting Fact
With the US Supreme Court’s 7-2 ruling, Bayer achieved its most important legal success since the Monsanto acquisition. Shortly thereafter, the company announced the carve-out of the US Roundup business into the new subsidiary “Ruveon”. Many analysts see this as an important step to limit legal risks and a potential starting point for a strategic realignment or a later break-up of the Group.
MUMAK.me Evaluation Phase 4: Positive = 1 MUMAK
Bayer AG
Market Sentiment Rating: positive
Technical Analysis
Assessment
The technical situation has recently brightened significantly. After a multi-month consolidation between approximately €34 and €49, the stock has now successfully broken out above its previous annual high. This has overcome a significant chart technical resistance and simultaneously marked a new multi-year high. The long-term uptrend since summer 2025 has been impressively confirmed and significantly accelerated.
Key Takeaway
- The breakout above the resistance at €49.30 represents a strong technical buy signal.
- The multi-month consolidation has been resolved upwards and should now serve as the basis for the next upward impulse.
- The long-term uptrend remains fully intact and has even accelerated recently.
Development in recent weeks/months
RSI (14)
Clearly positive
- Current RSI: approx. 84
- Stock is in overbought territory
- Strong momentum confirms the breakout
Interpretation: Short-term overbought and thus susceptible to minor profit-taking. However, in strong trend phases, a high RSI can persist for a longer period and is often an expression of exceptional buying power.
MACD (12/26/9)
Very positive
- MACD well above the signal line
- MACD continues to rise
- Momentum accelerates
Interpretation: Strong buy signal. The MACD confirms the breakout and continues to signal increasing upward momentum.
Bollinger Bands (20)
Very bullish
- Price is trading above the upper Bollinger Band
- Bands open significantly
- Volatility increases with the breakout
Interpretation: The breakout occurs with high momentum. A short-term technical breather may occur, but as long as the breakout above €49.30 is defended, the chart picture remains positive for us.
MUMAK.me Assessment Phase 5: Positive = 1 MUMAK
Bayer AG
Technical Analysis Rating: positive
What speaks for Bayer?
- Strong long-term demand factors in healthcare and agriculture
- Operational improvements and increasing profitability
- Leading market positions in pharma, consumer health, seeds, and crop protection
- Significantly reduced legal risk following the landmark ruling by the US Supreme Court
- Strategic carve-out of the US Roundup business increases transparency and opens up additional long-term value creation potential
What are the risks?
- Legal disputes related to glyphosate
- High debt
- Regulatory pressure and increasing environmental requirements
- Cash flow burden due to settlement payments and restructuring measures
- Patent expirations and increasing price pressure in the healthcare sector
What we are watching
- Development of order intake and revenue in 2026
- Development of profit margins
- Free operating cash flow compared to company forecast
- Progress in legal disputes and the group’s restructuring
Summary
The investment story of Bayer has improved significantly in recent weeks. In addition to operational recovery and rising profitability, the company achieved a decisive breakthrough in the glyphosate litigation with the landmark ruling by the US Supreme Court. The subsequent spin-off of the US Roundup business into the new subsidiary “Ruveon” reduces the complexity of the group and improves transparency for investors. Although legal risks and debt levels must continue to be monitored, a sustainable revaluation of the stock appears significantly more likely today than just a few months ago.
Rating According to the MUMAK Method
| Category | Rating |
|---|---|
| Geopolitics | Positive |
| Industry | Neutral |
| Fundamentals | Positive |
| News & Sentiment | Positive |
| Technical Analysis | Positive |
